PhysQuiz on APA 2021: Tardive Dyskinesia
Are you caught up on trials on tardive dyskinesia presented on APA 2021? Test your knowledge! 1. A...
Read More
Meeting Coverage
Findings Question Omega-3 Fatty Acids for High-Risk Patients
Prior research provides unclear results on the benefits of omega-3 fatty acids for the prevention of cardiovascular outcomes in patients with high cardiovascular risk. To determine the association of plasma levels of...
Read MoreLow- & High-Dose Aspirin Achieve Similar Results in CHD
United States guidelines suggest any aspirin dose between 81 mg and 325 mg daily for patients with coronary heart disease, while European guidelines that recommend 81 mg daily are mainly based on observational data and expert...
Read MoreDistress Doubles Cardiac Events in Young MI Survivors
With little known regarding psychological distress and residual risk of future cardiovascular events in young and middle-aged patients with a recent myocardial infarction (MI), researchers divided patients aged 18-61 with an MI...
Read MoreRenal Denervation Reduces BP in Resistant Hypertension
Previous studies suggest that endovascular renal denervation reduces blood pressure (BP) in patients with mild-to-moderate hypertension. However, its efficacy in patients with resistant hypertension remains unknow. To assess the...
Read MorePersonalized Rehab Benefits Older Patients With Heart Failure
Although research indicates that older adults hospitalized with acute decompensated heart failure (HF) have high rates of poor quality of life, delayed recovery, physical frailty, and frequent rehospitalization, well-established...
Read MorePrimary Debulking Surgery Bests Neoadjuvant Chemo in High-Grade Serous Ovarian Cancer
Earlier detection of primary ovarian tumor could extend survival in some patients When complete debulking is feasible, primary debulking surgery (PDS) may be superior to neoadjuvant chemotherapy (NACT) in women with high-grade...
Read MoreCirculating tumor DNA to evaluate response in children with neuroblastoma
In the phase 2 NANT2011-01 trial, levels of circulating tumor DNA (ctDNA) were evaluated during treatment. In patients with a clinical response, ctDNA becomes undetectable over time. Neuroblastoma is the most common extracranial...
Read MoreNovel drug combination for recurrent ovarian cancer
Mirvetuximab soravtansine, a folate receptor-targeting antibody-drug conjugate, in combination with bevacizumab, demonstrated impressive anti-cancer activity in the phase 1b FORWARD II trial. Mirvetuximab soravtansine (MIRV) is...
Read MoreAddition of abiraterone to ADT (plus docetaxel) nearly doubles survival of de novo metastatic prostate cancer
First results from the phase 3 PEACE-1 trial show that adding abiraterone to androgen deprivation therapy (ADT) plus docetaxel significantly improves progression-free survival in patients who present with de novo metastatic...
Read MoreNovel dual checkpoint blockade improves progression-free survival in melanoma
First results of the phase 3 RELATIVITY-047 trial validate the efficacy of dual checkpoint blockade demonstrated with the LAG-3 inhibitor relatlimab and nivolumab in patients with advanced melanoma. Lymphocyte-activation gene 3...
Read MoreImmune-related adverse events are associated with efficacy of atezolizumab in patients with advanced NSCLC
An exploratory post-hoc pooled analysis of three phase 3 trials with atezolizumab in patients with stage IV non-small cell lung cancer (NSCLC) – IMpower130, IMpower132, and IMpower150 – shows longer overall survival for patients...
Read MoreExcellent prognosis for breast cancer patients with ultra-low-risk gene signature
Analysis of 1,000 patients in the MINDACT trial identifies patients with ultra-low risk for distant recurrence. These patients could be candidates for further de-escalation of treatment. Gene signatures have proven successful in...
Read MorePatritumab deruxtecan (HER3-DXd) in EGFR TKI-resistant NSCLC
Patritumab deruxtecan (HER3-DXd), an antibody drug conjugate consisting of a monoclonal antibody to HER3 attached to a topoisomerase I, demonstrates anti-tumour activity across various EGFR TKI resistance mechanisms in heavily...
Read MoreLong-term results from ground-breaking melanoma trials
After initial results over 5 years ago, long-term follow-up data from 3 clinical trials – CheckMate 067, COLUMBUS, and ABC – show a durable and sustained clinical benefit for patients with melanoma. In the phase 3 CheckMate 067...
Read MorePembrolizumab benefits survival in MSI-H/dMMR metastastic colorectal cancer
First-line treatment of patients with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) with pembrolizumab improves overall survival, but the prespecified threshold for...
Read MorePost-nephrectomy pembrolizumab improves disease-free survival
First results of the phase 3 KEYNOTE 564 trial show that adjuvant therapy with pembrolizumab after nephrectomy enhances disease-free survival of patients treated for locoregional clear cell renal cell cancer (RCC). Nephrectomy...
Read MoreAdjuvant chemotherapy does not improve outcome in patients with locally advanced cervical cancer
Results of the randomized, phase 3 OUTBACK trial do not support the use of adjuvant chemotherapy after chemoradiation in women with locally advanced cervical cancer. At 5 years, both overall and progression-free survival were...
Read MoreOlaparib benefits early breast cancer patients with BRCA1/2 germline mutation
A first interim analysis of the OlympiA trial demonstrates significantly improved invasive disease-free survival in patients with high risk, HER2-negative, germline BRCA1/2-mutated primary breast cancer after 1 year of adjuvant...
Read MoreVenetoclax does not benefit ER-positive, HER2-negative metastatic breast cancer
Addition of the BCL2 inhibitor venetoclax to endocrine therapy does not improve clinical benefit in patients with ER-positive, HER2-negative, locally advanced/metastatic breast cancer, according to the primary analysis of the...
Read More